Johnson & Johnson gains smoldering multiple myeloma indication for Darzalex Faspro
The U.S. FDA has approved Johnson & Johnson's (JNJ) Darzalex Faspro (daratumumab and hyaluronidase) for a new...
Tag: JNJ
J&J wins FDA label expansion for Caplyta against depression
Johnson & Johnson (JNJ) announced on Thursday that the U.S. Food and Drug Administration has further expanded the...
J&J submits application to FDA for expanded use of Stelara
Johnson & Johnson (JNJ) has submitted a new application to the U.S. FDA to expand the use of Stelara (ustekinumab) for...
Eli Lilly, J&J working with Nvidia to boost AI capabilities
Johnson & Johnson (NYSE:JNJ) and Eli Lilly (NYSE:LLY) are utilizing Nvidia (NVDA) technology to either enhance their...
Kenvue, J&J sued by Texas over Tylenol marketing related to alleged autism risk
Texas Attorney General Ken Paxton has sued Kenvue (NYSE:KVUE) and Johnson & Johnson (NYSE:JNJ), alleging that the...
J&J touts Tremfya injection’s remission rate for Crohn’s disease
Johnson & Johnson (NYSE:JNJ) said that additional data from several phase 3 studies found that the subcutaneous...
Drug launch prices rise significantly outpacing inflation and GDP growth: ICER
The annual launch price of novel treatments approved from 2022 to 2024 continued to rise significantly in the U.S.,...
Johnson & Johnson succeeds in late-stage multiple myeloma trial
Johnson & Johnson (NYSE:JNJ) has announced that its late-stage trial for Tecvayli (teclistamab), used in combination...
J&J hit with first U.K. lawsuits over talc-related cancer claims
For the first time in the U.K., Johnson & Johnson (NYSE:JNJ) is facing lawsuits over claims that the company’s...
Johnson & Johnson outlines orthopaedics spin-off and targets 5.7% reported sales growth for 2025 amid accelerating MedTech and Innovative Medicine momentum
Earnings Call Insights: Johnson & Johnson (JNJ) Q3 2025 CEO Joaquin Duato highlighted "very strong third quarter...